LENZ Therapeutics, Inc. (LENZ)

NASDAQ: LENZ · IEX Real-Time Price · USD
18.41
-0.23 (-1.23%)
At close: May 22, 2024, 4:00 PM
17.49
-0.92 (-5.00%)
After-hours: May 22, 2024, 4:12 PM EDT
-1.23%
Market Cap 470.07M
Revenue (ttm) n/a
Net Income (ttm) -117.37M
Shares Out 25.53M
EPS (ttm) -15.85
PE Ratio n/a
Forward PE n/a
Dividend $7.21 (39.16%)
Ex-Dividend Date Mar 22, 2024
Volume 115,185
Open 18.74
Previous Close 18.64
Day's Range 18.31 - 19.43
52-Week Range 2.01 - 24.59
Beta n/a
Analysts Strong Buy
Price Target 31.33 (+70.18%)
Earnings Date May 8, 2024

About LENZ

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 25, 2021
Country Canada
Stock Exchange NASDAQ
Ticker Symbol LENZ
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for LENZ stock is "Strong Buy." The 12-month stock price forecast is $31.33, which is an increase of 70.18% from the latest price.

Price Target
$31.33
(70.18% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024

14 days ago - GlobeNewsWire

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidin...

21 days ago - GlobeNewsWire

Lenz Therapeutics' eye disease drugs meet main goal of late-stage study

Lenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study, sending its shares up nearly 23% before the bell.

7 weeks ago - Reuters

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop...

7 weeks ago - Business Wire

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop...

7 weeks ago - Business Wire

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress

SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that...

2 months ago - Business Wire